The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction
Abstract
Background—Angiotensin-converting enzyme 2 (ACE2) is a pleiotropic monocarboxypeptidase capable of metabolizing several peptide substrates. We hypothesized that ACE2 is a negative regulator of angiotensin II (Ang II)–mediated signaling and its adverse effects on the cardiovascular system. Methods and Results—Ang II infusion (1.5 mg · kg−1· d−1) for 14 days resulted in worsening cardiac fibrosis and pathological hypertrophy in ACE2 knockout (Ace2−/y) mice compared with wild-type (WT) mice. Daily treatment of Ang II–infused wild-type mice with recombinant human ACE2 (rhACE2; 2 mg · kg−1· d−1 IP) blunted the hypertrophic response and expression of hypertrophy markers and reduced Ang II–induced superoxide production. Ang II–mediated myocardial fibrosis and expression of procollagen type Iα1, procollagen type IIIα1, transforming growth factor-β1, and fibronectin were also suppressed by rhACE2. Ang II–induced diastolic dysfunction was inhibited by rhACE2 in association with reduced plasma and myocardial Ang II and increased plasma Ang 1-7 levels. rhACE2 treatment inhibited Ang II–mediated activation of protein kinase C-α and protein kinase C-β1 protein levels and phosphorylation of the extracellular signal-regulated 1/2, Janus kinase 2, and signal transducer and activator of transcription 3 signaling pathways in wild-type mice. A subpressor dose of Ang II (0.15 mg · kg−1· d−1) resulted in a milder phenotype that was strikingly attenuated by rhACE2 (2 mg · kg−1· d−1 IP). In adult ventricular cardiomyocytes and cardiofibroblasts, Ang II–mediated superoxide generation, collagen production, and extracellular signal-regulated 1/2 signaling were inhibited by rhACE2 in an Ang 1-7–dependent manner. Importantly, rhACE2 partially prevented the development of dilated cardiomyopathy in pressure-overloaded wild-type mice. Conclusions—Elevated Ang II induced hypertension, myocardial hypertrophy, fibrosis, and diastolic dysfunction, which were exacerbated by ACE2 deficiency, whereas rhACE2 attenuated Ang II– and pressure-overload–induced adverse myocardial remodeling. Hence, ACE2 is an important negative regulator of Ang II–induced heart disease and suppresses adverse myocardial remodeling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Weber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,027
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Regulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Self-citationHydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,407
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo Monitoring of ROS
Griendling, K. K., & FitzGerald, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000093660.86242.bb · Cited by 941
Cited by
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
Self-citationThe pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237
“bation of hypertension and cardiac hypertrophy induced by angiotensin II, [66] and maladaptive left ventricular remodeling after myocardial infarction.”
InfluentialRole of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,095
Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure
Patel, V. B., Zhong, J.-C., Grant, M. B., & Oudit, G. Y. (2016) · Circulation Research · doi:10.1161/circresaha.116.307708 · Cited by 833
Self-citationTikellis, C., & Thomas, M. C. (2012) · International Journal of Peptides · doi:10.1155/2012/256294 · Cited by 624
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
Cheng, H., Wang, Y., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25785 · Cited by 548
ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis
Simões e Silva, A., Silveira, K., Ferreira, A., & Teixeira, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12159 · Cited by 542
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Haschke, M., Schuster, M., Poglitsch, M., Loibner, H., Salzberg, M., Bruggisser, M., Penninger, J., & Krähenbühl, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0072-7 · Cited by 361
Self-citationThe renin-angiotensin system: going beyond the classical paradigms
Santos, R. A. S., Oudit, G. Y., Verano-Braga, T., Canta, G., Steckelings, U. M., & Bader, M. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00723.2018 · Cited by 340
Self-citationPatel, V. B., Clarke, N., Wang, Z., Fan, D., Parajuli, N., Basu, R., Putko, B., Kassiri, Z., Turner, A. J., & Oudit, G. Y. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.017 · Cited by 321
Self-citationAngiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury
Yang, P., Gu, H., Zhao, Z., Wang, W., Cao, B., Lai, C., Yang, X., Zhang, L., Duan, Y., Zhang, S., et al. (2014) · Scientific Reports · doi:10.1038/srep07027 · Cited by 283
Self-citationACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
Zipeto, D., Palmeira, J. D. F., Argañaraz, G. A., & Argañaraz, E. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576745 · Cited by 267
Angiotensin Converting Enzyme 2: A Double-Edged Sword
Wang, K., Gheblawi, M., & Oudit, G. Y. (2020) · Circulation · doi:10.1161/circulationaha.120.047049 · Cited by 265
“Soluble recombinant human ACE2 (rhACE2) is a promising therapeutic for SARS–CoV-2 through its ability to (1) sequester viral particles to prevent their interaction and subsequent entry through cell surface ACE2 and (2) limit activities of angiotensin II and increase levels of protective angiotensin 1–7.”
Self-citationZhang, Z., Tang, J., Song, J., Xie, M., Liu, Y., Dong, Z., Liu, X., Li, X., Zhang, M., Chen, Y., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.020 · Cited by 256
Self-citationPatel, V. B., Mori, J., McLean, B. A., Basu, R., Das, S. K., Ramprasath, T., Parajuli, N., Penninger, J. M., Grant, M. B., Lopaschuk, G. D., et al. (2016) · Diabetes · doi:10.2337/db15-0399 · Cited by 255
Self-citationSung, M. M., Das, S. K., Levasseur, J., Byrne, N. J., Fung, D., Kim, T. T., Masson, G., Boisvenue, J., Soltys, C.-L., Oudit, G. Y., et al. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001677 · Cited by 102
Self-citationSarzani, R., Giulietti, F., Di Pentima, C., Giordano, P., & Spannella, F. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2020 · Cited by 86
Sahara, M., Ikutomi, M., Morita, T., Minami, Y., Nakajima, T., Hirata, Y., Nagai, R., & Sata, M. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvt245 · Cited by 74
Ábrigo, J., Simon, F., Cabrera, D., & Cabello-Verrugio, C. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000452522 · Cited by 35
Chen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115370 · Cited by 19
Inhibition of Angiotensin II‐Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice
Choi, S. Y., Park, J. S., Roh, M. S., Kim, C., Kim, M. H., & Serebruany, V. (2017) · Lipids · doi:10.1007/s11745-017-4246-1 · Cited by 15
Metadata
- Authors
- Zhong, J., Basu, R., Guo, D., Chow, F. L., Byrns, S., Schuster, M., Loibner, H., Wang, X.-H., Penninger, J. M., Kassiri, Z., & Oudit, G. Y.
- Venue
- Circulation
- Published
- 2010-08-17
- Volume
- 122
- Issue
- 7
- Pages
- 717-728
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2029269323
- Cited by
- 457
- References
- 48
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.